C. difficile infection is overdiagnosed because the test is ordered too broadly. NAAT is highly sensitive — it detects colonization as well as infection. The clinical syndrome must be present before testing. A positive result in a patient without compatible diarrhea is colonization, not infection.
CLINICAL PRINTABLE
Coming Soon.
A one-page C. difficile Infection clinical reference is on the way.
1 · Recognition / Testing
- Suspect CDI with new clinically significant unexplained diarrhea (≥3 unformed stools in 24 hours), particularly after antibiotics, healthcare exposure, or in other risk contexts.
- Do not routinely test formed stool or asymptomatic patients — a positive test in a patient without compatible diarrhea reflects colonization, not infection.
- NAAT is highly sensitive for toxigenic organisms but can detect colonization; multistep toxin-based algorithms can improve clinical specificity depending on institutional testing strategy.
- Review laxatives, tube feeds, other medications, enteric infections, IBD, and noninfectious diarrhea before anchoring on a positive test.
- Severity assessment: non-severe (WBC <15,000, creatinine <1.5x baseline), severe (WBC ≥15,000 or creatinine ≥1.5x baseline), fulminant (hypotension, shock, ileus, megacolon).
2 · Treatment Pathway
Stop the inciting antibiotic
Stop the inciting antibiotic when feasible and reassess unnecessary acid suppression and other contributors. This alone may resolve mild CDI.
Non-severe initial CDI
Current guideline pathways generally favor fidaxomicin or oral vancomycin for initial CDI, with selection influenced by recurrence risk, access/cost, severity, and guideline context. Metronidazole is no longer preferred for initial CDI.
Severe CDI
Oral vancomycin 125 mg four times daily for 10 days. Fidaxomicin is an alternative with lower recurrence rates.
Fulminant CDI
Oral vancomycin 500 mg four times daily plus IV metronidazole. Rectal vancomycin if ileus is present. Surgical consultation for toxic megacolon or perforation.
Recurrent CDI
Recurrent CDI requires a recurrence-specific strategy — options include fidaxomicin/vancomycin taper strategies, microbiota-based therapies (fecal microbiota transplant, SER-109), and specialist-directed approaches depending on recurrence history and availability.
Infection control
Handwashing with soap and water — alcohol sanitizer is not reliably sporicidal against C. diff spores. Contact precautions, dedicated equipment, and environmental sporicidal cleaning.
3 · Expected Response / Failure
- Stool frequency and systemic symptoms should improve within 2–3 days of effective therapy.
- Do not use repeat 'test of cure' in a clinically recovered patient — NAAT can remain positive for weeks after successful treatment.
- Persistent/worsening diarrhea, leukocytosis/AKI, abdominal distention, ileus, or systemic deterioration requires severity reassessment and alternate/complicated-disease evaluation.
4 · Escalation
- Hypotension/shock, ileus, toxic megacolon concern, severe abdominal distention/peritonitis, significant AKI/systemic toxicity, or inability to maintain hydration.
- Fulminant disease requires hospital-level management and may require surgical consultation — subtotal colectomy for toxic megacolon or perforation.
- Infectious disease consultation for recurrent CDI, fulminant disease, or when microbiota-based therapy is being considered.
Apply It · Change One Detail
APPLY IT
A patient has formed stool but a positive NAAT obtained during an indiscriminate GI panel. That is not automatically CDI. The positive test reflects colonization in the absence of a compatible diarrheal syndrome — treatment is not indicated.
CHANGE ONE DETAIL
Change one detail — frequent new watery diarrhea after antibiotics with compatible clinical findings — and the same organism detection becomes much more meaningful. Now test and treat.
Bottom Line
C. diff is a clinical diarrheal syndrome supported by testing — not a laboratory result that needs treatment by itself. Test the right patient.
EVIDENCE & REFERENCES
- Kelly CR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278
- McDonald LC, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the IDSA and SHEA. Clin Infect Dis. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085